Data From Incyte's Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual CongressBusiness Wire • 05/12/21
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell LymphomaBusiness Wire • 05/11/21
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell LymphomaAccesswire • 05/11/21
Crescendo Biologics Further Strengthens Leadership Team With Appointment of Dr Michael Booth as Chief Financial OfficerBusiness Wire • 05/10/21
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/04/21
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 05/04/21
Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021Business Wire • 05/03/21
OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study AnalysesPRNewsWire • 04/23/21
Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic DermatitisBusiness Wire • 04/23/21
Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with VitiligoBusiness Wire • 04/23/21
Multiple Abstracts from Incyte's Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting ExperienceBusiness Wire • 04/20/21
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 StudyPRNewsWire • 04/20/21
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone LymphomaBusiness Wire • 04/19/21
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone LymphomaAccesswire • 04/19/21
Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main GoalBenzinga • 04/08/21
Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goalMarket Watch • 04/08/21